Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, recognizes ...
Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Alterity Therapeutics has appointed internationally recognised expert in neurodegenerative diseases Daniel O Claassen as chief medical advisor. ... Read More The post Alterity bolsters clinical ...
A Florida man with a terminal illness faces losing vital hospice care due to an administrative error, leaving his family in crisis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results